| Document |
Document Title |
|
WO/2024/059237A2 |
The invention provides novel glucocorticoid receptor agonists and immunoconjugates thereof, as well as pharmaceutical compositions and methods of preparation and use for treating various diseases and disorders (e.g., inflammatory disorde...
|
|
WO/2024/059608A1 |
Provided herein is a deuterated compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R15a, R15b, R16a, R16b, R17, R18, R19, R21a,...
|
|
WO/2024/035710A2 |
Described are compounds, compositions, and methods for delivery of therapeutic, diagnostic, or prophylactic agents (for example, a nucleic acid).
|
|
WO/2024/030825A1 |
The present invention relates to crystalline forms of the phosphate, mesylate, tartrate and citrate salts of compound A.
|
|
WO/2024/020953A1 |
Provided are a steroid compound for treating a central nervous system disease, a method for preparing same, and use and a pharmaceutical composition thereof. The steroid compound has a 9β,10α structure and has the following structural ...
|
|
WO/2024/026337A1 |
This invention relates to crystalline solvated forms of Compound (1) and pharmaceutical compositions thereof. Also disclosed herein are methods of making crystalline solvated solid forms of Compound (1), and methods of using the crystall...
|
|
WO/2024/026102A2 |
Prodrugs of testosterone and their use in alleviating, improving or reducing a risk of developing one or more conditions associated with androgen deprivation therapy (ADT), including orchiectomy or administration of a luteinizing hormone...
|
|
WO/2024/020520A2 |
The present disclosure provides for a synthetic strategy to incorporate a C12α-hydroxy group from the methylene (-CH2-) in a steroid backbone, combining synthetic chemistry and enzymology techniques to develop a selective inhibitor for ...
|
|
WO/2024/006811A2 |
The whole-cell accumulation of 345 diverse compounds in P. aeruginosa and E. coli have been assessed. While certain positively charged compounds were demonstrated to permeate both bacterial species, P. aeruginosa is more restrictive as c...
|
|
WO/2024/006288A1 |
Described are novel aminosterol compounds and additionally aminosterol-cyclodextrin formulations suitable for injectable administration, and methods of using the same.
|
|
WO/2024/005461A1 |
The present invention provides a novel linker compound and a ligand-drug conjugate therefor. This can stably deliver an active ingredient to a target site and rapidly release the active ingredient at the target site, and thus can increas...
|
|
WO/2023/250348A2 |
Exemplary materials, methods and techniques disclosed and contemplated herein generally relate to the photochemical synthesis of various deuterated 3-formyl indoles using deuterated glyoxylic acid (CDOCO2D).
|
|
WO/2023/247563A1 |
A compound of formula (I-A), R1 in each occurrence is selected from H, optionally substituted C1-12 alkyl and optionally substituted C6-20 aryl; R2 in each occurrence is selected from optionally substituted C1-12 alkyl and optionally sub...
|
|
WO/2023/237097A1 |
The present invention provides a 19-nor-C3,3-disubstituted C21-azacyclo-substituted steroid and a method for using same. In particular, the present invention relates to a compound represented by general formula (I), a method for preparin...
|
|
WO/2022/232602A9 |
Provided herein are compounds and pharmaceutical compositions useful in modulating kinase activity, and related diseases. These compounds are conjugates of glucocorticoids with rho-kinase inhibitors. Also provided herein are methods of t...
|
|
WO/2023/213151A1 |
The present invention provides a method for preparing abiraterone acetate and an intermediate thereof. The method particularly relates to the steps of: in an organic solvent, in the presence of a metal catalyst, reacting 3-site protected...
|
|
WO/2023/208988A1 |
The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt and/or solvates thereof. The invention further relates to the use of the compounds of the invention as anti-infective agents. In particular, ...
|
|
WO/2023/205801A2 |
The invention describes novel steroidal compounds, compositions containing the same, and methods of using the same as SREBP inhibitors, as LXR agonists, or as dual modulators of SREBP and LXR, to treat SREBP and/or LXR mediated diseases.
|
|
WO/2023/185673A1 |
Provided in the present invention are CDK8 inhibitors, a preparation method therefor and the use thereof, belonging to the field of biological medicines. The CDK8 inhibitors of the present invention are compounds represented by formula (...
|
|
WO/2023/178299A1 |
This disclosure relates to ganaxolone derivatives, as well as methods of using the compounds (e.g., for treatment of a disease or disorder), methods of making the compounds, and pharmaceutical compositions and kits comprising the same.
|
|
WO/2023/168974A1 |
A cholic acid derivative, a preparation method therefor, and an application thereof as a TGR5 allosteric agonist. using CA as a lead compound, modification is performed at positions 7, 12, and 24 thereof by means of a series of reactions...
|
|
WO/2023/159094A2 |
The present disclosure relates to processes for preparing 3α-hydroxy-3β-methoxymethyl-21-(1'-imidazolyl)-5α-pregnan
-20-one and pharmaceutically acceptable salts thereof. The present disclosure further relates to purified 3α-hydroxy-...
|
|
WO/2023/155846A1 |
The present invention relates to a 17-pyridyl-10α-methyl-steroid derivative and intermediate compound, a preparation method therefor, a use thereof, and a pharmaceutical composition thereof. A methyl group at a C-10 position of the ster...
|
|
WO/2023/144782A1 |
A pharmaceutical composition comprising a compound shown in formula (I) or a pharmaceutically acceptable salt thereof, a cyclodextrin, and optionally, a buffer. Additionally provided are a preparation method for the pharmaceutical compos...
|
|
WO/2023/137529A1 |
The present invention relates to compounds which are active against parasitic infections, such as protozoan parasite infections (including flagellate parasite infections, ciliate parasite infections, amoeba parasite infections and apicom...
|
|
WO/2023/131310A1 |
Disclosed in the present invention are a steroid compound, and a preparation method therefor and the use thereof. The structure of the steroid compound is as shown in formula I, and the definition of each substituent in the formula are a...
|
|
WO/2023/105494A1 |
The present invention relates to cationic steroid compounds of formula (I) and methods of obtaining them. The present invention further relates to the incorporation of such compounds in a polymeric matrix composition or a coating composi...
|
|
WO/2023/079362A1 |
Provided herein are compounds having the formula D1-L-D2, wherein D1 is a processable group, L is a linker, and D2 is a drug. Also described herein are pharmaceutical compositions comprising said compounds and methods for the treatment o...
|
|
WO/2023/076605A1 |
The present invention relates to lipid amine compounds of formula (A1) which are useful in the preparation of lipid nanoparticle compositions for delivery of therapeutic or prophylactic payload into cells.
|
|
WO/2023/076598A1 |
Provided are lipid amine compounds which are useful in the preparation of lipid nanoparticle compositions for delivery of therapeutic or prophylactic payload into cells.
|
|
WO/2023/059581A1 |
The invention provides heterobifunctional compounds comprising an effector protein binding moiety selected from mTor, PLK1, CDK1, CDK2, CDK9, BRD4, AURKA, AURKB, MEK, Src, c-KIT, KIF11, HSP90, tubulin, proteasome, topoisomerase or HD AC ...
|
|
WO/2023/025241A1 |
Disclosed are a novel precursor compound of abiraterone, and a preparation method therefor and a use thereof. The structure of the compound is shown in formula I. The present invention also provides a preparation method for the compound ...
|
|
WO/2023/020135A1 |
Disclosed in the present invention are an abiraterone derivative and a preparation method therefor. The abiraterone derivative provided by the present invention shows relatively few abdominal distension phenomena with respect to abirater...
|
|
WO/2023/011513A1 |
A following compound or a pharmaceutically acceptable salt, ester, optical isomer, stereoisomer, polymorph, solvate, N-oxide, isotope labeled-compound, metabolite, chelate, complex, clathrate, or prodrug thereof, and a pharmaceutical com...
|
|
WO/2023/008891A1 |
The present invention relates to a novel compound and a preparation method therefor. The compound according to the present invention exhibits inhibitory activity against the generation of TNF-α that is an inflammatory cytokine produced ...
|
|
WO/2023/009584A1 |
This invention relates to crystalline forms of anhydrous Compound (1) and pharmaceutical compositions thereof. Also disclosed herein are methods of making crystalline solid forms of Compound (1), and methods of using the crystalline form...
|
|
WO/2022/264975A1 |
The present invention addresses the problem of providing a method for efficiently producing α-tomatine. The method for producing α-tomatine that solves the problem includes a step for mixing at least one tomato plant body selected from...
|
|
WO/2022/251588A1 |
The invention provides heterobifunctional compounds, pharmaceutical compositions and their use in protein degradation and treating disease, such as cancer. The heterobifunctional compounds feature thalidomide derived moieties that binds ...
|
|
WO/2022/246907A1 |
Provided are a compound containing a 2,4-thiazole ring, a preparation method therefor, and an application thereof. The compound is represented by formula (X), where A is pyrazolopyrimidine or indole; Z is absent or is a carbonyl group; X...
|
|
WO/2022/232104A1 |
The disclosure relates to methods of treating depression, pain, a musculoskeletal disorder or a motor disorder such as essential tremor with Compound 1 or pharmaceutically acceptable salts thereof.
|
|
WO/2022/199408A1 |
Disclosed in the present invention are a novel injection polyaminopolycarboxylic acid-modified abiraterone derivative for treatment of prostate tumor, a pharmaceutical preparation containing the polyaminopolycarboxylic acid-modified abir...
|
|
WO/2022/196858A1 |
The present invention relates to a novel amino acid derivative, a preparation method therefor, and a pharmaceutical composition for treating hepatitis B or D, comprising same. A compound represented by chemical formula 1, according to th...
|
|
WO/2022/191092A1 |
The present invention addresses the problem of providing a new method for increasing the intracerebral histamine concentration. The present invention provides a compound represented by general formula (I) or a salt thereof. [In the formu...
|
|
WO/2022/178000A1 |
Disclosed herein are hemi-citrate salts of Compound (1), crystalline forms thereof, methods of their preparation, pharmaceutical compositions thereof, and methods of their use.
|
|
WO/2022/115381A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein ring D and the substituents are defined herein. Also provided are pharmaceutical compositions comprising a compound of Formula (I) or a p...
|
|
WO/2022/084752A1 |
The present invention relates to a process for the preparation of 21-(acetyloxy)-17-(1-oxopropoxy)-pregn-4-ene-3,20-dione (VI) having the formula below: Compound (VI) can be used as a precursor for the synthesis of Clascoterone, a steroi...
|
|
WO/2022/078483A1 |
A quaternary ammonium steroid compound represented by formula I, or an addition salt or a solvate of the quaternary ammonium steroid compound: wherein R 1 is H or CH 3CO; R 2 is CH 3 or -CH 2CH＝CH 2, and t is equal to 2 or 3; X is Cl, ...
|
|
WO/2022/040545A1 |
The invention relates to particular substituted (3α,5β)-3-hydroxy-pregnan-20-ones, in free or pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use ...
|
|
WO/2022/022623A1 |
The present invention belongs to the technical field of medicine, and particularly relates to an arenobufagin derivative, a preparation method therefor, a pharmaceutical composition thereof, and the use thereof. The arenobufagin derivati...
|
|
WO/2022/022559A1 |
The present disclosure relates to compounds which exhibit activity in the inhibition of platelet aggregation as well as pharmaceutical compositions comprising these compounds and methods of treatment of vascular diseases by administratio...
|
